Plain-English translation of NCT07293923 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing the Magenta Elevate™ percutaneous left ventricular assist device (pLVAD)—a small mechanical pump that is placed into your heart to help it pump blood when it suddenly fails. The study aims to see whether this device is safe and works well in patients experiencing cardiogenic shock, a life-threatening condition where the heart can no longer pump enough blood to the rest of the body. This treatment is designed as a temporary support while your heart recovers or while you await a longer-term solution.
Cardiogenic shock—when the heart suddenly loses the ability to pump effectively—is a medical emergency that can occur after a heart attack or during severe heart failure. Current treatments are limited, and doctors need new options to help patients survive this critical condition while they recover or receive other care.
You likely qualify if…
You likely don't qualify if…
If you are enrolled, you will receive the Magenta Elevate device, which is placed through a catheter (a thin tube) into your heart—a minimally invasive procedure done in a hospital setting. You will be closely monitored in the hospital during recovery, with regular heart function tests (such as echocardiograms) to evaluate how well the device is working. The study involves 10 patients total, and you will be followed to assess the device's safety and effectiveness in supporting your heart while it recovers.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
Georgia
Israel